Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2005-3-4
pubmed:abstractText
Preclinical evidence of synergy led to a phase I trial employing combretastatin A-4 phosphate (CA4P), a novel tubulin-binding antivascular drug, in combination with carboplatin.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1527-33
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15746056-Adult, pubmed-meshheading:15746056-Aged, pubmed-meshheading:15746056-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:15746056-Area Under Curve, pubmed-meshheading:15746056-Carboplatin, pubmed-meshheading:15746056-Dose-Response Relationship, Drug, pubmed-meshheading:15746056-Drug Interactions, pubmed-meshheading:15746056-Female, pubmed-meshheading:15746056-Humans, pubmed-meshheading:15746056-Infusions, Intravenous, pubmed-meshheading:15746056-Male, pubmed-meshheading:15746056-Middle Aged, pubmed-meshheading:15746056-Nausea, pubmed-meshheading:15746056-Neoplasms, pubmed-meshheading:15746056-Neutropenia, pubmed-meshheading:15746056-Stilbenes, pubmed-meshheading:15746056-Thrombocytopenia, pubmed-meshheading:15746056-Treatment Outcome, pubmed-meshheading:15746056-Vomiting
pubmed:year
2005
pubmed:articleTitle
Phase I trial of combretastatin a-4 phosphate with carboplatin.
pubmed:affiliation
University of Pennsylvania Cancer Center, University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA. bilenker@uphs.upenn.edu
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase I